Comparing Oncology Institute (NASDAQ:TOI) and Zicix (OTCMKTS:ZICXD)

Zicix (OTCMKTS:ZICXD) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Insider & Institutional Ownership

36.9% of Oncology Institute shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Zicix and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zicix	N/A	N/A	N/A
Oncology Institute	-13.21%	-1,527.21%	-35.30%

Earnings & Valuation

This table compares Zicix and Oncology Institute”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zicix	N/A	N/A	N/A	($100.14)	-0.03
Oncology Institute	$393.41 million	0.83	-$64.66 million	($0.64)	-5.20

Zicix has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Zicix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Zicix and Oncology Institute, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zicix	0	0	0	0	0.00
Oncology Institute	1	0	3	1	2.80

Oncology Institute has a consensus target price of $6.50, indicating a potential upside of 95.20%. Given Oncology Institute’s stronger consensus rating and higher probable upside, analysts clearly believe Oncology Institute is more favorable than Zicix.

Risk & Volatility

Zicix has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.

Summary

Oncology Institute beats Zicix on 8 of the 13 factors compared between the two stocks.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.